Selskabsmeddelelse23.7.2024, 06.30Cyxone: The board decides on a rights issue of a maximum of approximately SEK 23 million to finance continued development of rabeximod and T20K
Pressemeddelelse20.11.2023, 08.22Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor
Selskabsmeddelelse9.10.2023, 06.38Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K
Selskabsmeddelelse29.8.2023, 17.03Cyxone revises strategy for commercial alignment targeting valuable market opportunities
Pressemeddelelse31.5.2023, 12.00Cyxone receives Intention to Grant from the European Patent Office for the divisional patent of T20K